- Conditions
- Medullary Thyroid Cancer
- Interventions
- cabozantinib
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 5
- States / cities
- Stanford, California • Boston, Massachusetts • Detroit, Michigan + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1657–1680
of 9,379
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Web-based coping skills training, Online disease education
- Behavioral
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 10
- States / cities
- San Francisco, California • Chicago, Illinois • Indianopolis, Indiana + 7 more
- Conditions
- GI Colonization of Vancomycin-resistant Enterococcus
- Interventions
- probiotics, yogurt
- Dietary Supplement
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
- Interventions
- US-ATG-F, Placebo
- Biological
- Lead sponsor
- Neovii Biotech
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 26
- States / cities
- Duarte, California • Stanford, California • Gainesville, Florida + 20 more
- Conditions
- Parkinson Disease
- Interventions
- Placebo, UCB0022
- Other · Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Parkinson Disease, GBA Gene Mutation, Gaucher Disease
- Interventions
- PET scan, neuroQWERTY
- Diagnostic Test
- Lead sponsor
- Pacific Parkinson's Research Centre
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
- Interventions
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 2.0 mg OPT-302, 0.5 mg ranibizumab, Sham
- Biological · Procedure
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more
- Conditions
- Respiratory Depression, Respiratory Failure, Ventilatory Depression
- Interventions
- Endotracheal Tube Fastener
- Device
- Lead sponsor
- Hollister Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Gresham, Oregon • Portland, Oregon • Vancouver, Washington
- Conditions
- Sleep
- Interventions
- Breathing Group 1, Breathing Group 2
- Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Warts
- Interventions
- Resiquimod
- Drug
- Lead sponsor
- Graceway Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
- Interventions
- tucatinib, trastuzumab, fulvestrant
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more
- Conditions
- Rhinoconjunctivitis
- Interventions
- Cat-PAD, Placebo
- Drug
- Lead sponsor
- Circassia Limited
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 1,408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 52
- States / cities
- Rolling Hills Estates, California • Colorado Springs, Colorado • Denver, Colorado + 49 more
- Conditions
- Type 2 Diabetes
- Interventions
- Colesevelam hydrochloride
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Tuscumbia, Alabama • Jonesboro, Arkansas + 59 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Placebo, RG7774
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more
- Conditions
- Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Interventions
- Tovinontrine (CRD-750), Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 19 more
- Conditions
- Parkinson Disease
- Interventions
- DaTscan
- Drug
- Lead sponsor
- Ken Marek, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 952 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 17 more
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
- Drug
- Lead sponsor
- Envisia Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 14
- States / cities
- Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more
- Conditions
- Malignant Neoplasm
- Interventions
- Netupitant, Palonosetron Hydrochloride, Questionnaire Administration
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8
- Interventions
- Activity Monitor, Quality-of-Life Assessment, Questionnaire Administration
- Device · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Omaha, Nebraska • New York, New York • Portland, Oregon
- Conditions
- Surgical Site Infection
- Interventions
- Mupirocin, Chlorhexidine gluconate, Cefazolin, Vancomycin, Nasal Povidone Iodine
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 23,005 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 11
- States / cities
- Miami, Florida • Iowa City, Iowa • Baltimore, Maryland + 8 more
- Conditions
- Chronic Hand Eczema
- Interventions
- ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream
- Drug
- Lead sponsor
- Arcutis Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 25
- States / cities
- Beverly Hills, California • Encino, California • Fremont, California + 21 more
- Conditions
- AMD
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • Miami, Florida • Atlanta, Georgia + 11 more
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Interventions
- melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization
- Drug · Procedure
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 12
- States / cities
- Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more